Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS IG AUDITING PHARMACEUTICAL PRICING, IMPACT OF PBMs ON PATIENT QUALITY OF CARE; KENNEDY/KASSEBAUM BILL WOULD ADD FUNDS FOR IG FRAUD INVESTIGATIONS

Executive Summary

The HHS Inspector General is conducting audits of drug pricing practices in the context of Medicare/Medicaid rebate programs, physician acquisition costs and anti-kickback law violations, Helen Trilling, a partner at the Washington, D.C. firm Hogan & Hartson, told a May 14 meeting of the Food & Drug Law Institute.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel